You are here: Industry Insights > CV

News List

Low-Cost, Fixed-Dose Polypill Reduces Risk for Major CV Events drugs
August 26, 2019
Use of a four-component polypill can effectively reduce the risk for major cardiovascular events, according to a study published in the issue of The Lancet.
Serelaxin Does Not Lower CV Death in Acute Heart Failure drugs
August 22, 2019
An infusion of serelaxin does not result in a lower incidence of death from cardiovascular causes or worsening of heart failure among patients hospitalized for acute heart failure...
Better CV Health in Midlife Tied to Reduced Dementia Risk Later drugs
August 09, 2019
Adherence to the Life Simple 7 ideal cardiovascular health recommendations in midlife is associated with reduced incidence of dementia later in life, according to a study published online in The BMJ.
Lifestyle Counseling Frequency, CV Outcomes Linked in Diabetes drugs
August 07, 2019
For hyperglycemic adults with diabetes, a higher frequency of lifestyle counseling is associated with a lower incidence of a composite outcome of death and cardiovascular events...
Changes in Radial Pulse During Menopause May Reflect CV Risk drugs
July 31, 2019
Changes in the harmonics of the radial pulse wave during menopause may reflect cardiovascular risk...
Carotid Atherosclerosis Predicts CV Events in Psoriatic Disease drugs
June 06, 2019
Carotid Atherosclerosis Predicts CV Events in Psoriatic Disease.
Increase in CV Mortality Smaller With Medicaid Expansion drugs
June 06, 2019
Increase in CV Mortality Smaller With Medicaid Expansion.
Don’t let difficult substances control your cleaning validation europeanpharmaceuticalreview
May 17, 2019
Don’t let difficult substances control your cleaning validation.
Janssen gets FDA approval for Invokana to reduce risk of CV events pharmaceutical-technology
November 01, 2018
Janssen Pharmaceutical has received approval from the US Food and Drug Administration (FDA) for the use of Invokana (canagliflozin) to minimise the risk of major adverse cardiovascular (CV) events in adults.
J&J's Invokana becomes first FDA-approved oral diabetes drug to reduce cardiovascular event risk pharmafile
November 01, 2018
The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of major adverse cardiovascular (CV) events, making it the “first and only oral diabetes treatment.....

Previous page 1 2 3 Next page